Reckitt Benckiser share price: Jefferies continues to see group as ‘underperform’

Tsveta van Son
  • February 7th 2019, 08:07
  • Last Updated: October 21st 2019, 15:13

Jefferies continues to see Reckitt Benckiser (LON:RB) as an ‘underperform,’ noting that a weak cold and flu season in the US has impacted the sales of the group’s over-the-counter medicine Mucinex, Citywire reports. The comments come as the company prepares to update investors on its full-year performance on February 18.

Reckitt Benckiser’s share price fell in the previous session, giving up 1.73 percent to 5,857.00p and underperforming the broader UK market, with the benchmark FTSE 100 index closing 0.06 percent lower at 7,173.09. The group’s shares have lost just under 10 percent of their value over the past year, as compared with about a 0.4-percent gain in the Footsie.

Jefferies sees RB as ‘underperform’

Jefferies retained its ‘underperform’ rating on Reckitt Benckiser yesterday, with a price target of 5,000p on the shares. Citywire quoted the broker’s analyst Martin Deboo as commenting that there was  ‘acute downward pressure on Mucinex’, which accounts for five percent of the company’s sales and more of profits.

“We expect this to inhibit full-year 2019 guidance confidence ahead of the crunch prelims meeting on 18 February,” the analyst pointed out.

Reckitt Benckiser’s results will come after last month, the consumer goods giant announced that Rakesh Kapoor had decided to retire by the end of the year after more than eight years as CEO.

Other analysts on blue-chip group

The 16 analysts offering 12-month price targets for Reckitt Benckiser for the Financial Times have a median target of 6,845.00p on the shares, with a high estimate of 9,000.00p and a low estimate of 5,000.00p. As of February 2, the consensus forecast amongst 21 polled investment analysts covering the blue-chip group advises investors to hold their position in the company.  

As of 08:09 GMT, Thursday, 07 February, Reckitt Benckiser Group Plc share price is 5,857.00p.

About the author

Tsveta van Son
Tsveta van Son is part of Invezz’s journalist team. She has a BA degree in European Studies and a MA degree in Nordic Studies from Sofia University and has also attended the University of Iceland. While she covers a variety of investment news, she is particularly interested in developments in the field of renewable energy.

Leave a Reply

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.